Top-News

Avidity Biosciences Aktie News

Aktie
WKN:  A2P5NK ISIN:  US05370A1088 US-Symbol:  RNA Branche:  Biotechnologie Land:  USA
71,54 $
-0,04 $
-0,06%
61,333 € 04.12.25
Depot/Watchlist
Marktkapitalisierung *
7,32 Mrd. €
Streubesitz
0,88%
KGV
-11,59
Index-Zuordnung
-

Avidity Biosciences News

07.08.25 - PR Newswire
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights PR Newswire
28.07.25 - PR Newswire
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-​desiran) for Treatment of DM1 and Provides ...
23.07.25 - PR Newswire
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 ...
11.06.25 - PR Newswire
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD ...
09.06.25 - PR Newswire
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in ...
09.06.25 - PR Newswire
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in ...
21.05.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.05.25 - PR Newswire
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights PR Newswire
06.05.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire
21.04.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.04.25 - PR Newswire
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-​desiran) for Treatment of Myotonic Dystrophy Type 1 PR Newswire
01.04.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire
31.03.25 - PR Newswire
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral ...
21.03.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
17.03.25 - PR Newswire
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in ...
12.03.25 - PR Newswire
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference PR Newswire
28.02.25 - PR Newswire
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases PR Newswire
27.02.25 - PR Newswire
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights PR Newswire
25.02.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire
21.02.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »